Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Mast Cell

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    55 result(s) found for: Mast Cell. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2008-000972-25 Sponsor Protocol Number: AB06006 Start Date*: 2013-06-06
    Sponsor Name:AB SCIENCE
    Full Title: A 24-week with possible extension, prospective, multicentre, randomized, double blind, placebo-controlled, 2-parallel group with a randomization 1:1, Phase III study to compare efficacy and safety ...
    Medical condition: Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis with handicaps
    Disease: Version SOC Term Classification Code Term Level
    9.1 10026891 Mastocytosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) CZ (Completed) SK (Completed) LV (Completed) AT (Completed) DE (Prohibited by CA) GB (Completed) IT (Completed) BG (Completed) HU (Completed) GR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-003268-25 Sponsor Protocol Number: RC31/19/0504 Start Date*: 2020-10-08
    Sponsor Name:CHU Toulouse
    Full Title: Hydroxychloroquine in isolated cutaneous mastocytosis patients or indolent systemic mastocytosis with associated skin involvement patients: proof of concept study
    Medical condition: mastocytosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042949 Systemic mastocytosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001447-39 Sponsor Protocol Number: AB15003 Start Date*: 2019-10-21
    Sponsor Name:AB SCIENCE
    Full Title: A 24-week with possible extension, prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel group with a randomization 1:1, phase III study to compare efficacy and safety ...
    Medical condition: Smouldering or Indolent Severe Systemic mastocytosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) DE (Ongoing) PL (Ongoing) RO (Ongoing) LT (Completed) NL (Temporarily Halted) IT (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2008-006183-11 Sponsor Protocol Number: CA180-287 Start Date*: 2010-01-22
    Sponsor Name:UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II
    Full Title: Multicenter, Open-Label, Single Arm Phase II Clinical Trial of Dasatinib in the Treatment of Systemic Mastocytosis (SM)
    Medical condition: Systemic mastocytosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10042949 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004604-37 Sponsor Protocol Number: NL55891.078.15 Start Date*: 2017-02-17
    Sponsor Name:Erasmus University Medical Center
    Full Title: Aspirin provocation of patients with Systemic Mastocytosis
    Medical condition: Systemic mastocytosis is a myeloproliferative disorder in which there is an accumulation of aberrant mast cells. It has various subtypes, ranging from indolent to aggressive mastocytosis. Symptoms ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002452-16 Sponsor Protocol Number: PTO95105013 Start Date*: 2020-02-04
    Sponsor Name:UMC Utrecht
    Full Title: Inhibition of Mast cell Activation in AtheroScleroTic lesions using an Anti-IgE antibody approach (MAST-trial)
    Medical condition: Atherosclerosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004113-85 Sponsor Protocol Number: PA101-SM-02 Start Date*: 2015-04-16
    Sponsor Name:Patara Pharma, LLC
    Full Title: Randomized, Double-blind, Placebo-controlled, Crossover Design, Efficacy and Safety Study with PA101 in Patients with Indolent Systemic Mastocytosis
    Medical condition: Indolent Systemic Mastocytosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10005329 - Blood and lymphatic system disorders 10042949 Systemic mastocytosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-000280-42 Sponsor Protocol Number: CPKC412D2201 Start Date*: 2008-08-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A single arm, Phase II, Open-label Study to determine the efficacy of 100 mg twice daily oral dosing of midostaurin administered to patients with Agressive Systemic Mastocytosis or Mast Cell Leukem...
    Medical condition: Agressive Systemic Mastocytosis (ASM) or Mast Cell Leukemia (MCL) +/- an Associated Hematological Clonal Non-Mast Cell Lineage Disease (AHNMD)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004851 10056453 Aggressive systemic mastocytosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) IT (Completed) DE (Completed) NO (Completed) AT (Completed) GB (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-019189-94 Sponsor Protocol Number: CLMAST01 Start Date*: 2010-07-22
    Sponsor Name:Dr. Luis Escribano
    Full Title: Tratamiento con inhibidores de tirosina quinasas en pacientes con variantes de mastocitosis sistémica de mal pronóstico: ensayo clínico para sujetos sin mutación D816V de KIT y búsqueda de inhibido...
    Medical condition: Mastocitosis sistémica
    Disease: Version SOC Term Classification Code Term Level
    11 10042949 Mastocitosis sistémica LLT
    11 10056453 Mastocitosis sistémica agresiva LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000588-99 Sponsor Protocol Number: BLU-285-2203 Start Date*: 2019-03-15
    Sponsor Name:Blueprint Medicines Corporation
    Full Title: A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indole...
    Medical condition: Indolent Systemic Mastocytosis (ISM)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042949 Systemic mastocytosis PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056452 Indolent systemic mastocytosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Ongoing) DE (Ongoing) ES (Ongoing) NL (Ongoing) DK (Ongoing) IT (Ongoing) SE (Ongoing) FR (Ongoing) NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-019344-39 Sponsor Protocol Number: BUCUM1 Start Date*: 2010-08-09
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: Double-blind, triple cross-over, placebo-controlled study to assess the efficacy, mechanisms, and safety of treatment with bilastine 20 mg, 40 mg and 80 mg in cold contact urticaria (CCU) Compound:...
    Medical condition: Cold contact urticaria
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004868-22 Sponsor Protocol Number: UMCG41973 Start Date*: 2013-07-09
    Sponsor Name:University Medical Center Groningen
    Full Title: Phase II single arm open pilot study to demonstrate the efficacy of midostaurin in symptom improvement and decrease of mast cell burden in patients with indolent or smoldering systemic mastocytosis
    Medical condition: Indolent or smoldering mastocytosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004094-93 Sponsor Protocol Number: PAFCUTIII Start Date*: 2012-04-19
    Sponsor Name:Allergie-Centrum Charité
    Full Title: Double-blind, three-way cross-over, placebo controlled study to assess the efficacy, safety and mechanisms of treatment with rupatadine 20 and 40mg in cold contact urticaria (CCU)
    Medical condition: Cold contact urticaria
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10009869 Cold urticaria LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-005173-28 Sponsor Protocol Number: BLU-263-1201 Start Date*: 2021-09-06
    Sponsor Name:Blueprint Medicines Corporation
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis
    Medical condition: Indolent Systemic Mastocytosis (ISM) and monoclonal Mast Cell Activation Syndrome (mMCAS)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10056452 Indolent systemic mastocytosis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing) DE (Ongoing) FR (Ongoing) ES (Ongoing) AT (Ongoing) NL (Ongoing) PT (Ongoing) IT (Ongoing) DK (Ongoing) SE (Ongoing) NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-001535-87 Sponsor Protocol Number: BLU-263-2101 Start Date*: 2023-02-03
    Sponsor Name:Blueprint Medicines Corporation
    Full Title: A Phase 1/2, open-label, 2-arm study evaluating BLU-263 as monotherapy and in combination with azacitidine, in patients with KIT altered hematologic malignancies
    Medical condition: Advanced Systemic Mastocytosis (AdvSM)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042949 Systemic mastocytosis PT
    26.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056453 Aggressive systemic mastocytosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000594-81 Sponsor Protocol Number: S65020 Start Date*: 2021-05-07
    Sponsor Name:University Hospitals Leuven (UZ Leuven)
    Full Title: The effect of corticotropin release hormone on duodenal markers and gastric sensorimotor function in healthy volunteers
    Medical condition: To assess the effect of the CRH on duodenal mast cell count, eosinophil count, immune activation, mucosal permeability and gastric sensorimotor function and gastrointestinal symptoms.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021001-21 Sponsor Protocol Number: SMART-2010-1 Start Date*: 2010-09-27
    Sponsor Name:Allergie-Centrum-Charité
    Full Title: An exploratory, randomised, double-blind, placebo controlled crossover study to assess the efficacy of 20 mg Rupatadine on the treatment of mastocytosis symptoms
    Medical condition: Mastocytosis is characterized by an excessive increase in the number of mast cells in different tissues. Symptoms result either from organ infiltration or frequently from the release of proinflamma...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10052577 Pure dermal mastocytosis LLT
    12.1 10056452 Indolent systemic mastocytosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-004734-15 Sponsor Protocol Number: EBio Start Date*: 2019-06-03
    Sponsor Name:Universitätsklinikum Erlangen
    Full Title: EBIO – Enthesitis biopsy study
    Medical condition: Psoriatic arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000797-35 Sponsor Protocol Number: EC11-287 Start Date*: 2013-05-24
    Sponsor Name:Hospital Virgen de la Salud, Toledo (Spain).
    Full Title: Clinical Trial with Cladribine (2-CDA) and Pegylated Interpheron Alfa-2a in patients with advanced systemic mastocytosis carrying D816V KIT mutation (or different mutations involving exon 17 of KIT).
    Medical condition: Advanced systemic mastocytosis carrying the D816V KIT mutation (or different exon 17 KIT mutations).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-005406-96 Sponsor Protocol Number: AB20006 Start Date*: 2022-10-07
    Sponsor Name:AB Science
    Full Title: A 24-week, multicenter, randomized, double blind, placebo-controlled, dose-range finding phase II study to compare efficacy and safety of oral masitinib to placebo in treatment of patients with sev...
    Medical condition: severe mast cell activation syndrome (MCAS) with handicap unresponsive to optimal symptomatic treatment
    Disease: Version SOC Term Classification Code Term Level
    20.1 10005329 - Blood and lymphatic system disorders 10075217 Mast cell activation syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Ongoing) BE (Ongoing) DE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 02 18:03:33 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA